OakChart

Ocular Therapeutix Inc

OCULHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.66+0.05 (0.76%)
2026-11-11 22:51 CET
Market cap
1,451.66 USD m
Revenue, TTM
50.38 USD m
Net income, TTM
-326.81 USD m
Free cash flow, TTM
-267.04 USD m
EPS diluted, TTM
-1.46
P/E
-
Compare

Price

OCUL against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.0012.007.7M15.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OCULclose 6.6620-day 6.7750-day 8.17200-day 8.946.6652w low

59.5% under the 52-week high of 16.44 on 8 Dec 2025. 52-week low 6.00 on 19 Oct 2026. Last 15 sessions, 24.5% high to low

Volume 0.96× normal · the line is the 50-bar volume average

Profile

OCUL
52-week range, 6% of the way up
6.0016.44

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

IndexRUT
Employees325
IPOJul 25, 2014
Beta1.23
ATR, 14d0.46
Rel volume0.96
Short float14.44%
Insider own8.58%
Inst own88.74%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.47B
Enterprise Value1.01B
Income-326.81M
Sales50.38M
Book/sh2.01
Cash/sh2.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees325
IPOJul 25, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S29.09
P/B3.32
P/C2.76
P/FCF-
EV/EBITDA-
EV/Sales20.14
Quick Ratio9.05
Current Ratio9.12
Debt/Eq0.18
LT Debt/Eq0.18
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.46
EPS next Y-1.64
EPS next Q-0.43
EPS this Y-12.08%
EPS next Y-3.20%
EPS next 5Y4.77%
EPS past 3/5Y-15.40% 11.13%
Sales past 3/5Y0.29% 24.45%
EPS Y/Y TTM-1.35%
Sales Y/Y TTM-9.68%
EPS Q/Q-11.37%
Sales Q/Q-11.48%
EarningsNov 09 BMO
EPS/Sales Surpr.-15.54% -9.80%

Ownership

Insider Own8.58%
Insider Trans-0.75%
Inst Own88.74%
Inst Trans1.45%
ROA-64.30%
ROE-93.48%
ROIC-63.08%
Gross Margin84.89%
Oper. Margin-680.90%
Profit Margin-648.64%
SMA20-1.61%
SMA50-18.52%
SMA200-25.54%
Trades-

Technical

Shs Outstand219.88M
Shs Float200.76M
Short Float14.44%
Short Ratio9.32
Short Interest29.00M
52W High16.44 -59.49%
52W Low6.00 11.00%
Volatility7.79% 6.74%
ATR (14)0.46
RSI (14)42.71
Beta1.23
Rel Volume0.96
Avg Volume3.11M
Volume2,988,315

Performance

Perf Week-6.72%
Perf Month-8.01%
Perf Quarter-34.06%
Perf Half Y-27.92%
Perf YTD-45.14%
Perf Year-40.64%
Perf 3Y216.39%
Perf 5Y-11.32%
Perf 10Y-3.06%
Recom1.08
Target Price26.38
Prev Close6.61
Price6.66
Change %0.76%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSBuy$14+110.2%
Sep 15, 2025InitiatedCChardan Capital MarketsBuy$21+215.3%
Apr 08, 2025InitiatedWWilliam BlairOutperform
Mar 18, 2025InitiatedRRBC Capital MktsOutperform$17+155.3%
Mar 11, 2025InitiatedNNeedhamBuy$15+125.2%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Jun 20, 2024UpgradeTTD CowenHold → Buy$7 → $11+65.2%
May 31, 2024ResumedPPiper SandlerOverweight$15+125.2%
Feb 09, 2024InitiatedBBofA SecuritiesBuy$15+125.2%
Apr 21, 2023InitiatedRRobert W. BairdOutperform$18+170.3%

Peers

Mkt cap
TickerCompanyMkt cap
EYPTEyePoint Inc30.74M
KODKodiak Sciences Inc6.87B
FDMT4D Molecular Therapeutics Inc717.62M
REGNRegeneron Pharmaceuticals Inc99.23B
RGNXRegenxbio Inc560.06M
OTLKOutlook Therapeutics Inc117.10M
TARSTarsus Pharmaceuticals Inc3.78B
OCGNOcugen Inc325.87M
HROWHarrow Inc1.10B
ABBVAbbvie Inc521.41B

Insider trading

latest 14 of 62
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Saroj NamrataChief Business OfficerNov 05 '26Sale6.5535,370231,674220,522Nov 09 04:29 PM
NAMRATA SAROJOfficerNov 05 '26Proposed Sale6.5535,370231,836Nov 05 04:24 PM
Anderman ToddChief Legal OfficerOct 08 '26Sale7.2911,98487,363140,484Oct 13 05:01 PM
TODD ANDERMANOfficerOct 08 '26Proposed Sale7.2911,98487,315Oct 08 04:28 PM
Kaiser PeterChief Development OfficerOct 02 '26Sale7.059,99070,430254,388Oct 06 04:44 PM
Heier Jeffrey S.Chief Scientific OfficerOct 02 '26Sale7.0510,86976,626307,457Oct 06 04:43 PM
PETER KAZUO KAISEROfficerOct 02 '26Proposed Sale7.059,99070,459Oct 02 04:08 PM
JEFFREY S. HEIEROfficerOct 02 '26Proposed Sale7.0510,86976,639Oct 02 04:05 PM
Notman DonaldChief Operating OfficerAug 31 '26Sale10.241,09911,254366,529Sep 02 04:01 PM
DONALD D NOTMAN JR.OfficerAug 31 '26Proposed Sale10.241,09911,252Aug 31 04:02 PM
Kaiser PeterChief Development OfficerAug 24 '26Sale10.773,03532,687264,378Aug 26 05:59 PM
Nayak SanjayChief Strategy OfficerAug 24 '26Sale10.781,89720,450326,898Aug 26 05:58 PM
Heier Jeffrey S.Chief Scientific OfficerAug 24 '26Sale10.783,29635,531318,326Aug 26 05:57 PM
Dugel PravinSee RemarksAug 24 '26Sale10.7721,649233,1602,525,429Aug 26 05:56 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
PJPInvesco Pharmaceuticals ETFAUM: 603.92M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.420-0.364-0.42012.8714.2712
2026Q22026-08-03-0.350-0.396-0.35013.4813.2011
2026Q12026-05-05-0.400-0.315-0.39510.7912.7212
2025Q42026-02-05-0.290-0.321-0.29013.2516.1313
2025Q32025-11-04-0.380-0.372-0.37714.5414.6413
2025Q22025-08-05-0.390-0.357-0.39313.4613.4613
2025Q12025-05-05-0.380-0.294-0.37810.7017.0213
2024Q42025-03-03-0.290-0.254-0.28817.0817.1510
2024Q32024-11-14-0.220-0.243-0.21915.4317.139
2024Q22024-08-07-0.260-0.221-0.26416.4415.858
2024Q12024-05-07-0.490-0.193-0.49114.7715.368
2023Q42024-03-11-0.350-0.296-0.34614.8015.708
2023Q32023-11-07-0.006-0.287-0.25315.0815.237
2023Q22023-08-07-0.260-0.301-0.26515.1914.627
2023Q12023-05-08-0.390-0.263-0.39213.3714.096
2022Q42023-03-06-0.200-0.253-0.20214.0813.536

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.910-1.774-1.9084.234.55
2020FY-2.560-1.181-2.56217.4022.33
2021FY-0.090-1.030-0.97743.5245.03
2022FY-0.920-0.947-0.92451.4950.82
2023FY-1.010-0.985-1.01658.4459.39
2024FY-1.220-1.180-1.22363.7263.74
2025FY-1.420-1.453-1.42051.9554.77
2026FY--1.592--51.38
2027FY--1.643--90.32
2028FY--1.226--270.09
2029FY--0.183--624.46
2030FY-0.918--991.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-10131613.7812.9016.35
2026Q4S2026-11-09131513.8412.9017.13
2026Q4S2026-10-28130014.1613.2017.13
2026Q4S2026-10-21130114.1613.2017.13
2026Q4S2026-10-17131114.1613.2017.13
2026Q4S2026-10-09134214.1613.2017.13
2026Q4S2026-08-14124214.1913.2017.13
2026Q4S2026-08-07125114.2313.2017.13
2026Q4S2026-08-03124114.1313.2016.02
2026Q4S2026-07-19110013.8611.6016.02
2026Q4S2026-06-16112513.8611.6016.02
2026Q4S2026-06-15112513.8611.6016.02
2026Q4S2026-06-07112513.8611.6016.02
2026Q4S2026-05-05122513.7911.6016.02

Estimate history

EPS, annual-2.2-1.574-1.908-2.562-0.977-0.924-1.016-1.223-1.42-1.4559
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.219-0.288-0.378-0.393-0.377-0.29-0.395-0.35-0.42
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.9231.994.22717.40343.52251.49458.44363.72351.95150.38
Period201720182019202020212022202320242025TTM
Sales, quarterly15.42517.08210.69813.45914.54413.2510.78513.47512.874
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual29.65841.51850.33475.99776.73277.202114.963157.749215.928219.885
Period201720182019202020212022202320242025MRQ
Shares, quarterly156.655157.749159.262172.925174.95215.928218.897219.589219.885
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue50.3851.9563.7258.4451.4943.5217.404.231.99
Cost of Goods Sold Incl. D&A7.626.575.635.284.544.413.473.592.75
Gross Profit42.7745.3858.1053.1646.9539.1213.930.64-0.76
Selling, General and Administrative Excl. Other385.84315.39229.88135.54125.61117.1576.7886.4458.36
Research and Development245.94197.10127.6461.0553.4650.0828.6941.0936.91
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-343.07-270.02-171.78-82.38-78.65-78.04-62.85-85.80-59.12
Interest Expense11.2111.8413.5811.347.026.676.776.101.74
Unusual Expense-3.652.4728.43-9.00-13.84-78.1286.19-4.310.00
Net Income Before Taxes-326.81-265.94-193.51-80.74-71.04-6.55-155.64-86.37-59.98
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-326.81-265.94-193.51-80.74-71.04-6.55-155.64-86.37-59.98
Net Income From Continuing Operations-326.81-265.94-193.51-80.74-71.04-6.55-155.64-86.37-59.98
Net Income-326.81-265.94-193.51-80.74-71.04-6.55-155.64-86.37-59.98
EPS (Recurring)-1.46-1.41-1.10-1.09-1.05-1.64-1.57-1.97-1.57
EPS (Basic, Before Extraordinaries)-1.46-1.42-1.22-1.01-0.92-0.09-2.56-1.91-1.57
EPS (Diluted)-1.46-1.42-1.22-1.02-0.92-0.98-2.56-1.91-1.57
EBITDA-336.23-265.69-168.00-79.40-76.55-75.62-60.07-83.27-56.83
Non-Operating Income (Expense)23.8218.3820.283.980.800.030.171.220.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense56.6643.1833.1117.8216.9614.987.538.767.48
Price To Sales Ratio34.3343.7521.216.534.2013.1672.2642.3176.23
Gross Margin84.8987.3591.1790.9691.1889.8880.0615.07-38.24
Operating Margin-680.90-519.75-269.57-140.96-152.74-179.30-361.13-2,029.86-2,970.75
Net Margin-648.64-511.90-303.67-138.14-137.95-15.06-894.31-2,043.34-3,013.97
Shares Outstanding219.88215.93157.75114.9677.2076.7376.0050.3341.52
Market Capitalization1,451.661,451.661,342.63491.58216.40533.971,558.76189.91163.56

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue12.8713.4710.7913.2514.5413.4610.7017.08
Cost of Goods Sold Incl. D&A2.682.011.331.591.771.941.261.23
Gross Profit10.1911.469.4611.6612.7711.529.4415.85
Selling, General and Administrative Excl. Other108.0593.57102.8081.4281.4779.1673.3566.43
Research and Development74.7954.1466.2150.8052.3651.0842.8640.99
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-97.86-82.11-93.34-69.76-68.70-67.64-63.92-50.58
Interest Expense2.812.792.782.833.003.022.983.11
Unusual Expense-0.91-0.69-1.46-0.591.450.640.98-0.62
Net Income Before Taxes-94.78-78.76-88.61-64.65-69.42-67.81-64.05-48.39
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-94.78-78.76-88.61-64.65-69.42-67.81-64.05-48.39
Net Income From Continuing Operations-94.78-78.76-88.61-64.65-69.42-67.81-64.05-48.39
Net Income-94.78-78.76-88.61-64.65-69.42-67.81-64.05-48.39
EPS (Recurring)-0.42-0.35-0.40-0.29-0.37-0.39-0.37-0.29
EPS (Basic, Before Extraordinaries)-0.42-0.35-0.40-0.29-0.38-0.39-0.38-0.29
EPS (Diluted)-0.42-0.35-0.40-0.29-0.38-0.39-0.38-0.29
EBITDA-95.41-80.26-92.06-68.51-67.63-66.61-62.94-49.62
Non-Operating Income (Expense)4.985.456.057.343.733.483.834.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.0714.6515.5811.3611.699.6810.467.20
Price To Sales Ratio34.3342.4436.4852.0938.5428.2720.8222.52
Gross Margin79.1785.0887.6887.9787.8085.5688.2092.80
Operating Margin-760.12-609.34-865.46-526.49-472.35-502.57-597.47-296.08
Net Margin-736.23-584.51-821.62-487.95-477.30-503.86-598.74-283.27
Shares Outstanding219.88219.59218.90215.93174.95172.93159.26157.75
Market Capitalization1,451.662,150.191,843.852,586.392,034.001,478.301,165.631,342.63

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments737.06392.10195.96102.30164.16228.0654.4454.0641.54
Short Term Receivables30.6532.3926.1821.3221.1412.252.550.200.23
Inventories3.563.042.311.971.251.200.950.220.12
Other Current Assets10.8613.467.794.034.754.652.231.711.34
Total Current Assets782.13440.99232.24129.63191.30246.1660.1756.1943.23
Net Property, Plant & Equipment24.3115.3318.2117.9011.8213.9416.8110.2410.48
Total Investments and Advances1.611.611.611.761.761.761.766.611.61
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets3.08--------
Other Assets0.000.000.000.000.000.000.000.000.11
Total Assets811.14457.94252.06149.29204.89261.8678.7473.0455.43
Short Term Debt Incl. Current Port. of LT Debt2.821.931.591.601.629.651.130.005.54
Accounts Payable4.154.184.395.124.592.713.272.963.57
Other Current Liabilities43.8435.2428.9224.6720.1214.317.636.194.31
Total Current Liabilities50.8141.3534.9031.3926.3426.6612.039.1613.43
Long Term Debt74.1573.8581.8062.6857.3648.7958.2224.7912.47
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities3.08--------
Other Liabilities28.7927.3944.2319.8333.19110.3112.123.223.39
Total Liabilities156.83142.59160.93113.91116.89185.7782.3737.1729.28
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity654.31315.3491.1335.3888.0076.09-3.6335.8826.15
Total Shareholders Equity654.31315.3491.1335.3888.0076.09-3.6335.8826.15
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity654.31315.3491.1335.3888.0076.09-3.6335.8826.15
Total Liabilities & Stockholders Equity811.14457.94252.06149.29204.89261.8678.7473.0455.43
Book Value Per Share3.032.000.790.461.151.00-0.070.860.88
Tangible Book Value Per Share3.032.000.790.461.151.00-0.070.860.88
Full-Time Employees325274267274228181161167119
Price to Book Ratio3.303.8045.104.686.0820.67-54.774.613.64
Return on Assets-41.91-54.51-40.23-40.11-2.81-91.39-113.81-93.37-97.24
Return on Equity-54.85-95.21-127.64-115.16-7.99-429.55-535.72-193.41-162.21
Return on Invested Capital-36.51-49.72-46.69-72.44-4.51-124.62-158.23-98.87-164.14
Quick Ratio15.3210.596.594.077.229.194.926.113.21
Current Ratio15.3910.666.664.137.269.235.006.143.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-326.81-265.94-193.51-80.74-71.04-6.55-155.64-86.37-59.98
Depreciation6.814.323.792.982.112.422.772.532.29
Other Funds (Non Cash)61.0149.0265.2714.937.98-58.5298.138.147.88
Funds from Operations-258.99-212.59-124.45-62.82-60.95-62.65-54.73-75.70-49.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.857.71-10.23-7.411.35-2.901.18-1.880.58
Cash from Operating Activities-253.14-204.88-134.68-70.23-59.60-65.55-53.55-77.58-49.23
Capital Expenditures-13.90-12.01-1.29-6.09-3.71-1.19-0.84-2.24-1.89
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.130.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-13.90-11.88-1.29-6.09-3.71-1.19-0.84-2.24-1.89
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock452.88561.7215.76118.661.453.30228.0138.0762.27
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock452.88561.7215.76118.661.453.30228.0138.0762.27
Proceedsfrom Stock Options445.75539.590.00117.260.00-0.28224.6837.5461.57
Issuance or Reduction of Debt, Net0.000.00316.3551.160.00-0.450.0037.276.38
Change in Long Term Debt0.000.00316.3551.160.00-0.450.0037.276.38
Issuance of Long Term Debt0.000.00316.3577.290.003.723.2037.2712.03
Reduction of Long Term Debt0.000.000.00-26.120.00-4.17-3.200.00-5.66
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities452.88561.72332.11169.831.452.85228.0175.3468.64
Net Change in Cash185.84344.96196.1593.51-61.86-63.89173.62-4.4717.52
Free Cash Flow-267.04-216.89-135.97-76.32-63.32-66.74-54.40-79.82-51.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments530.61598.64666.70737.06344.77391.13
Short Term Receivables31.3930.2624.3530.6530.7730.41
Inventories4.263.833.743.563.493.04
Other Current Assets8.3411.7011.2110.867.958.79
Total Current Assets574.60644.43706.00782.13386.98433.38
Net Property, Plant & Equipment26.2125.2824.9224.3122.2916.34
Total Investments and Advances1.611.611.611.611.611.61
Intangible Assets-0.000.000.000.000.00
Deferred Tax Assets---3.08--
Other Assets3.230.000.000.000.000.00
Total Assets605.65671.32732.53811.14410.88451.33
Short Term Debt Incl. Current Port. of LT Debt2.833.123.172.822.762.62
Accounts Payable5.757.008.034.156.265.89
Other Current Liabilities54.4439.0636.4943.8440.2734.42
Total Current Liabilities63.0249.1747.6850.8149.2942.93
Long Term Debt77.1876.2676.2974.1574.2574.31
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---3.08--
Other Liabilities24.5025.8426.9828.7929.1128.17
Total Liabilities164.70151.28150.96156.83152.65145.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity440.95520.04581.57654.31258.23305.92
Total Shareholders Equity440.95520.04581.57654.31258.23305.92
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity440.95520.04581.57654.31258.23305.92
Total Liabilities & Stockholders Equity605.65671.32732.53811.14410.88451.33
Book Value Per Share2.012.372.663.031.481.77
Tangible Book Value Per Share2.012.372.663.031.481.77
Full-Time Employees---325--
Price to Book Ratio3.303.702.808.226.615.56
Return on Assets-64.30-53.70-51.03-41.91-55.41-44.76
Return on Equity-93.48-72.99-68.55-54.85-81.83-63.41
Return on Invested Capital-18.29-13.21-13.47-8.88-20.88-17.83
Quick Ratio9.0513.0314.7315.327.7810.02
Current Ratio9.1213.1114.8115.397.8510.09

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-94.78-78.76-88.61-64.65-69.42-67.81
Depreciation2.431.851.281.251.071.03
Other Funds (Non Cash)14.7814.6020.3711.2613.9011.00
Funds from Operations-77.57-62.31-66.95-52.15-54.45-55.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.95-4.960.96-2.103.730.55
Cash from Operating Activities-65.62-67.27-65.99-54.25-50.73-55.24
Capital Expenditures-3.03-3.37-4.66-2.84-5.99-1.25
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.13
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-3.03-3.37-4.66-2.84-5.99-1.11
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.622.580.29449.3810.3697.81
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.622.580.29449.3810.3697.81
Proceedsfrom Stock Options0.000.900.00444.850.0094.74
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.622.580.29449.3810.3697.81
Net Change in Cash-68.03-68.06-70.36392.29-46.3641.45
Free Cash Flow-68.65-70.64-70.66-57.09-56.72-56.48

Revenue breakdown

Collaboration revenue2024: 262.00K 2025: 128.00K
Product2024: 63.46M 2025: 51.82M
United States2024: 63.72M 2025: 51.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.44%29.0M200.8M3.05M
2026-10-1514.33%28.8M200.8M2.90M
2026-09-3014.65%29.4M200.7M2.65M
2026-09-1514.91%29.9M200.7M2.63M
2026-08-3113.98%28.1M200.7M2.64M
2026-08-1414.19%28.5M200.9M2.57M
2026-07-3113.29%26.7M201.1M2.68M
2026-07-1513.48%27.0M200.5M2.86M
2026-06-3013.31%26.7M200.5M3.13M
2026-06-1513.20%26.5M200.5M3.01M
2026-05-2912.56%25.1M199.8M3.74M
2026-05-1512.40%24.8M199.8M5.24M
2026-04-3012.52%24.8M198.0M5.61M
2026-04-1512.46%24.5M196.8M5.89M
2026-03-3112.80%25.2M196.9M6.31M
2026-03-1312.03%23.7M196.9M6.19M
2026-02-278.96%17.6M196.9M5.78M
2026-02-137.47%14.7M196.9M4.30M
2026-01-306.05%11.5M190.3M3.83M
2026-01-156.87%12.8M186.3M3.45M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.002.656.700.000.0000.000.000.954-0.0370.001
call3.001.655.700.0015.7090.000.000.930-0.0360.001
call4.000.654.702.3511.09910.000.000.899-0.0340.002
call5.000.204.002.949.3933.000.000.850-0.0290.002
call6.000.002.750.916.3763950.000.749-0.0220.003
call7.000.050.250.170.93274029.000.477-0.0390.004
call8.000.000.050.050.9416410.000.112-0.0100.002
call9.000.000.050.041.3164360.000.086-0.0120.002
call10.000.000.050.041.5854860.000.072-0.0120.001
call11.000.002.150.371.9272080.000.064-0.0140.001
call12.000.000.500.052.17640.000.000.058-0.0150.001
call13.000.002.150.152.3971120.000.054-0.0160.001
call14.000.002.150.402.5973.000.000.051-0.0160.001
call15.000.002.150.052.7804.000.000.049-0.0160.001
call16.000.002.150.002.9350.000.000.047-0.0160.001
call17.000.002.150.003.0880.000.000.045-0.0170.001
call18.000.002.150.003.2290.000.000.043-0.0170.001
put2.000.002.150.006.5640.000.00-0.046-0.0370.001
put3.000.002.150.004.5700.000.00-0.070-0.0360.001
put4.000.002.150.003.2010.000.00-0.101-0.0330.002
put5.000.002.150.002.1220.000.00-0.150-0.0290.002
put6.000.000.200.201.7671160.00-0.335-0.0450.004
put7.000.201.801.153.9022352.00-0.523-0.0390.004
put8.001.052.551.474.05064.000.00-0.886-0.0100.002
put9.000.353.502.504.52054.000.00-0.914-0.0110.002
put10.001.355.402.947.19510.000.00-0.927-0.0120.001
put11.002.356.400.007.6050.000.00-0.936-0.0130.001
put12.003.307.400.007.9640.000.00-0.942-0.0140.001
put13.004.308.400.008.2830.000.00-0.946-0.0140.001
put14.005.309.400.008.5680.000.00-0.949-0.0140.001
put15.006.3010.400.008.8270.000.00-0.951-0.0150.001
put16.007.3011.400.009.0640.000.00-0.954-0.0150.001
put17.008.3012.409.149.2810.000.00-0.955-0.0150.001
put18.009.3013.400.009.4830.000.00-0.957-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-103Initial statement of beneficial ownership of securities2026-11-06SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-098-KCurrent report2026-11-06SEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-168-KCurrent report2026-10-14SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-08144Filing for proposed sale of securities under Rule 144.SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-31144Filing for proposed sale of securities under Rule 144.SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-29SCHEDULE 13G/ASEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100231.67K1
2026-1000234.42K3
2026-090000
2026-0800333.08K5
2026-070000
2026-0600122.63K1
2026-0500237.79K4
2026-040000
2026-030000
2026-02461.35K11.75M11
2026-010000
2025-120000
2025-1100613.45K5

Institutional holders

Manager% owned
FMR LLC15.10%
Deep Track Capital, LP8.99%
BlackRock, Inc.8.85%
Avoro Capital Advisors LLC5.73%
SUMMER ROAD LLC5.68%
Venrock Adviser, LLC4.73%
VANGUARD CAPITAL MANAGEMENT LLC4.03%
PRICE T ROWE ASSOCIATES INC /MD/3.48%
Logos Global Management LP2.42%
GEODE CAPITAL MANAGEMENT, LLC2.40%

Funds

Fund% owned
Fidelity Growth Company Fund4.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.41%
Fidelity Growth Company K6 Fund1.23%
Fidelity Series Growth Company Fund1.19%
Fidelity Small Cap Index Fund1.03%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
T. Rowe Price New Horizons Fund, Inc.0.82%
iShares Russell 2000 Growth ETF0.72%
Invesco Pharmaceuticals ETF0.68%

OakChart. OCUL. Cached 15 minutes.